A contractor that makes ingredients for Johnson & Johnson’s COVID-19 vaccine said in a filing Monday that federal regulators ordered a stoppage to its production of the drug substance for the duration of an inspection at a Maryland facility that was previously plagued with a contamination issue. Emergent BioSolutions, which has a contract to manufacture bulk drug substance for Johnson & Johnson’s COVID-19 vaccine, said in an SEC filing that the Food and Drug Administration (FDA) requested a pause in production of any new material at its Bayview facility in Baltimore, Maryland, while regulators carry out an inspection.  The FDA also requested that existing vaccine substance be put into quarantine for the duration of the probe. Federal regulators launched the inspection on April 12. The company did not immediately return a request from The Epoch Times for information on how long the manufacturing pause could last and for comment on …